Sanofi Expands Immunology Portfolio With Blueprint Acquisition
By Katie Anderson, Chief Editor, Pharmaceutical Online
Sanofi expanded its portfolio in immunology with the completed acquisition of Blueprint Medicines Corporation.
The acquisition includes a rare immunology disease medicine Ayvakit/Ayvakyt (avapritinib); potent and highly selective KIT D816V inhibitor elenestinib, which has limited central nervous system penetration; and BLU-808, an investigational oral, highly potent and selective wild-type KIT inhibitor.
Following its acceptance of the tendered shares, Sanofi completed its acquisition of Blueprint through the merger of a wholly owned subsidiary of Sanofi with and into Blueprint, pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with Blueprint continuing as the surviving corporation, and becoming an indirect, wholly owned subsidiary of Sanofi.
Sanofi is financing the transaction with a combination of cash on hand and proceeds from commercial paper issuances and the acquisition will not have a significant impact on Sanofi’s financial guidance for 2025. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026.
"The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company. This acquisition is fully aligned with our strategic intent to strengthen our existing therapeutic areas, to bring relevant and differentiated medicines to patients and to secure attractive returns to our shareholders. It complements recent acquisitions of early-stage medicines that remain our main field of interest. Sanofi still retains a sizeable capacity for further acquisitions. We are excited to welcome Blueprint’s talented people and we look forward to chasing the miracles of science together. This makes sense for science, for both companies, for healthcare professionals, and – most of all – for patients,” commented Sanofi CEO Paul Hudson in a press release.